AeolAeolic (linguistics)
AeolAustralian Engineering OnLine (Taren Point, NSW, Australia)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Biotechnology company Aeolus Pharmaceuticals Inc (Other OTC:AOLS) reported on Wednesday the launch of an open-label, single centre, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of AEOL 10150 administered by subcutaneous injection in healthy subjects for national defense and oncology.
Authority (BARDA) to develop AEOL 10150 Pulmonary Acute Radiation Syndrome.
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) disclosed on Friday the exercise of USD3m in additional contract options for AEOL 10150 by Biomedical Advanced Research and Development Authority (BARDA) under the USD118m advanced research and development contract.
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) disclosed on Wednesday that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) seeking protection in all PCT contracting countries for its lead compound, AEOL 10150.
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) revealed on Thursday the receipt of notice for AEOL 10150 for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.
Aeolus Pharmaceuticals, a biotechnology company, has filed a provisional application including new inventions resulting from research and development on its lead compound, AEOL 10150, with the US Patent and Trademark Office, it was reported on Friday.
M2 EQUITYBITES-December 9, 2013-Aeolus Pharmaceuticals files provisional application for AEOL 10150 with US Patent and Trademark Office
M2 EQUITYBITES-December 6, 2013-Aeolus Pharmaceuticals Inc submits application for new patent for AEOL 10150 for use in radiation exposure
M2 PHARMA-June 1, 2012-Aeolus Pharmaceuticals report study results showing AEOL 10150 reduces lung damage after Neupogen treatment due to radiation exposure(C)2012 M2 COMMUNICATIONS
In February 2011 BARDA awarded Aeolus a five-year advanced research and development contract to support the development of AEOL 10150 as a medical countermeasure against the pulmonary effects of acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), valued up to USD118m.